Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help With Low Libido in Men?
The honest map across 8 low-libido scenarios in men — etiology, what's been studied, and where validated FDA-approved testosterone replacement and HCG rule.
WHICH LOW LIBIDO CONTEXT?
Low Libido Context
Animal Studies
Human Trials
Hypogonadotropic hypogonadism
FDA-approved HCG indication
Primary hypogonadism contributing
exogenous TRT validated
Age-related testosterone decline
andropause context
Medication-induced low libido
SSRIs, opioids, finasteride
Psychogenic low libido
depression, stress, relationship
Metabolic syndrome contribution
obesity, diabetes, sleep apnea
Investigational research therapy
men with low desire
Adjunct alongside testosterone
off-label combination context
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Low libido in men has well-characterized validated approaches. Foundations include comprehensive evaluation by urology, endocrinology, men's health, or primary care. Workup covers hormone testing including total testosterone, free testosterone, LH, FSH, prolactin, SHBG, TSH, and estradiol. Mental health screening and individualized therapy matching follow per Endocrine Society guidelines.
HCG is FDA-approved for male hypogonadotropic hypogonadism. The compound stimulates endogenous testicular testosterone production via LH-receptor activation, preserving testicular volume and supporting fertility.
Bremelanotide (PT-141) is FDA-approved as Vyleesi for premenopausal female HSDD only. Off-label male use exists but lacks Phase 3 outcome evidence.
Kisspeptin is investigational. Phase 2 trials from the Dhillo group at Imperial College London include men with low sexual desire.
Tesamorelin holds FDA approval for HIV-lipodystrophy. Low-libido-specific evidence is absent.
The honest framing: HCG holds FDA-approved validated role when hypogonadism contributes. Exogenous testosterone replacement (gels, patches, injections, pellets) is FDA-approved alternative with different mechanism. Comprehensive evaluation precedes pharmacotherapy. For broader context, see Peptides for Sexual Health, Peptides for Testosterone Support, and Peptides for Erectile Dysfunction.
HCG vs exogenous testosterone replacement for low libido
Two FDA-approved approaches with different trade-offs
Exogenous testosterone replacement therapy (TRT) is FDA-approved for male hypogonadism with multiple formulations. Options include testosterone gels (AndroGel, Testim, Fortesta), patches (Androderm), injections (testosterone cypionate, enanthate, undecanoate), and pellets (Testopel). TRT provides direct testosterone replacement with effects on libido and sexual function. The approach suppresses endogenous LH and FSH, reducing testicular volume and impairing fertility.
HCG is FDA-approved for male hypogonadotropic hypogonadism with mechanism of LH-receptor activation driving endogenous testicular testosterone production. The compound preserves testicular volume and supports fertility maintenance. Administration is intramuscular or subcutaneous injection. HCG can be used as monotherapy in hypogonadotropic hypogonadism or as adjunct alongside exogenous testosterone for fertility preservation in select cases.
PSI's reading: both HCG and exogenous TRT are validated FDA-approved options for hypogonadism-related low libido with different trade-offs. HCG is appropriate for hypogonadotropic origin and patients prioritizing fertility preservation. Exogenous TRT is appropriate for primary hypogonadism and patients without fertility concerns. Combination protocols exist in specialty practice but lack Phase 3 outcome evidence as combination therapy. Endocrinology, urology, or men's health specialty guidance ensures matching.
Bremelanotide off-label vs testosterone replacement for low libido
Off-label peptide use vs FDA-approved validated standard-of-care
Testosterone replacement therapy holds FDA approvals for male hypogonadism with substantial Phase 3 evidence. The Endocrine Society clinical practice guideline supports testosterone therapy effects on sexual function and libido in documented hypogonadism. Multiple formulations provide flexibility for patient selection.
Bremelanotide is FDA-approved as Vyleesi for premenopausal female HSDD only. Off-label male use exists in some men's health clinic contexts. Mechanism is melanocortin-4 receptor agonism with central sexual desire pathway activation. Phase 3 outcome trial evidence in male low libido is limited. The off-label male use is not standard urology or endocrinology practice.
PSI's reading: for hypogonadism-related low libido in men, FDA-approved testosterone replacement therapy or HCG is the validated foundation. Bremelanotide off-label male use lacks Phase 3 evidence and exposes patients to side effects (nausea, flushing, cardiovascular caution) without validated efficacy. Comprehensive evaluation by urology, endocrinology, men's health, or primary care precedes pharmacotherapy decisions.
Kisspeptin investigational vs validated testosterone replacement
Phase 2 next-generation research vs current evidence-graded standards
Kisspeptin Phase 2 trials from the Dhillo group at Imperial College London report effects on sexual desire and limbic activation in men with low sexual desire. The compound activates KISS1R receptors on hypothalamic GnRH neurons with central reproductive axis effects. Mechanism is novel relative to direct testosterone replacement. Phase 3 development is ongoing. Not FDA-approved as of 2026.
Validated FDA-approved options for low libido include testosterone replacement therapy and HCG when hypogonadism is documented. Both have substantial Phase 3 evidence and FDA-approved positioning. Insurance coverage exists for FDA-approved indications. Specialty guidance under urology, endocrinology, or men's health is appropriate.
PSI's reading: Kisspeptin is promising for next-generation low desire therapy pending Phase 3 readout. Until FDA approval, validated FDA-approved options including testosterone replacement and HCG hold current evidence-graded positioning. Phase 2 trial enrollment provides monitored access for patients interested in investigational therapy. Off-label compounded kisspeptin lacks Phase 3 evidence and is not validated practice.
Comprehensive low libido evaluation vs single-compound approach
Multi-factor workup beyond pharmacotherapy
Low libido in men has multiple distinct etiologies. Hormonal factors include hypogonadism (primary or hypogonadotropic), elevated prolactin, thyroid dysfunction, and elevated estradiol. Medication side effects from SSRIs, opioids, finasteride, and others contribute. Psychogenic factors include depression, stress, performance anxiety, and relationship issues. Metabolic factors include obesity, diabetes, sleep apnea, and metabolic syndrome. Comprehensive workup identifies contributing factors per Endocrine Society guidelines.
Validated FDA-approved approaches address each contributor. Testosterone replacement therapy or HCG addresses hypogonadism. Treatment of comorbid sleep apnea (CPAP) improves testosterone and libido. Weight management improves multiple contributors. Medication review and alternatives address pharmaceutical contributors. Mental health treatment addresses depression. Sex therapy addresses psychological and relational factors.
PSI's reading: comprehensive low libido evaluation by urology, endocrinology, men's health, or primary care identifies contributing factors and matches treatment. Single-compound peptide approach without comprehensive evaluation bypasses essential workup. Validated FDA-approved options including testosterone replacement, HCG, and lifestyle interventions form the foundation. Off-label peptides without FDA-approved indication evidence are not validated practice.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 4 peptides discussed for low libido in men, one holds FDA approval for hypogonadism with secondary libido relevance. HCG holds FDA approval for male hypogonadotropic hypogonadism. The compound stimulates endogenous testosterone production via LH-receptor activation. When low libido is secondary to documented hypogonadism, HCG and testosterone replacement are validated options. Bremelanotide holds FDA approval as Vyleesi for premenopausal female HSDD with off-label male use lacking Phase 3 evidence. Kisspeptin is investigational with Phase 2 trials including men with low desire. Tesamorelin holds FDA approval for HIV-lipodystrophy with cardiometabolic adjacent context. Validated FDA-approved approaches dominate. They include testosterone replacement therapy, HCG, comprehensive evaluation, lifestyle optimization, and sex therapy.
HCG
FDA-approved for male hypogonadotropic hypogonadism with validated role for low libido secondary to documented low testosterone. Preserves fertility and testicular volume.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Context | Animal Studies | Human Trials |
|---|---|---|
Male hypogonadotropic hypogonadism FDA-approved indication | 8 Strong LH-receptor activation evidence in testicular function models. | 6 Substantial Phase 3 evidence supporting FDA approval; testosterone restoration with effects on sexual function and libido when hypogonadism is the etiology. Liu 2009 |
Low libido secondary to hypogonadism validated when low testosterone contributes | 6 Testosterone restoration effects on male sexual function and desire in animal models. | 4 Endocrine Society guidelines support testosterone therapy effects on sexual function in documented hypogonadism. Bhasin 2018 |
Kisspeptin
Investigational; Phase 2 trials at Imperial College London include men with low sexual desire. Phase 3 development ongoing. Not FDA-approved.
| Context | Animal Studies | Human Trials |
|---|---|---|
Men with low sexual desire investigational; Phase 2 evidence | 6 Strong KISS1R agonist effects on reproductive behavior in male animal models. | 4 Phase 2 trials at Imperial College London demonstrated effects on sexual desire and limbic activation in men with low desire. Mills 2023 |
Reproductive endocrine assessment research diagnostic context | 6 GnRH stimulation effects in animal models. | 4 Research use as GnRH-stimulation diagnostic tool in reproductive endocrinology research. Comninos 2017 |
Bremelanotide (PT-141)
FDA-approved Vyleesi for premenopausal female HSDD only. Off-label male use lacks Phase 3 evidence comparable to validated testosterone replacement.
| Context | Animal Studies | Human Trials |
|---|---|---|
Premenopausal female HSDD FDA-approved Vyleesi indication | 6 Melanocortin receptor agonist effects on sexual behavior in animal models. | 6 Phase 3 RECONNECT trials supporting 2019 FDA approval. Kingsberg 2019 |
Off-label male low libido off-label use without Phase 3 evidence | 4 Some animal evidence for male sexual function effects. | 2 Limited off-label use studies; validated testosterone replacement is FDA-approved foundation for hypogonadism-related low libido. |
Tesamorelin
FDA-approved for HIV-associated lipodystrophy. Cardiometabolic adjacent context. Low-libido-specific evidence absent.
| Context | Animal Studies | Human Trials |
|---|---|---|
HIV-associated lipodystrophy FDA-approved indication | 6 GHRH analog effects on body composition with visceral fat targeting in animal models. | 6 Phase 3 trials supporting FDA approval; visceral fat reduction with cardiometabolic improvements. Falutz 2007 |
Low libido (off-label) absent low-libido-specific evidence | 0 No animal evidence specific to low libido. | 0 No human low-libido-specific trials. Validated FDA-approved testosterone replacement dominates. |
What's Marketed vs What's Studied
6 common claims, corrected.
“Peptides restore male desire reliably without medical evaluation.”
Low libido in men has multiple distinct etiologies (hormonal, medication-induced, psychogenic, metabolic). Comprehensive evaluation by urology, endocrinology, or men's health determines appropriate therapy. Self-treatment with peptides bypasses essential clinical workup.
“Bremelanotide (PT-141) is FDA-approved for male low libido.”
Bremelanotide (Vyleesi) is FDA-approved exclusively for premenopausal female HSDD. Off-label male use exists but is not FDA-approved and lacks Phase 3 outcome evidence comparable to validated testosterone replacement therapy.
“HCG fixes low libido in any man.”
HCG is FDA-approved for documented hypogonadotropic hypogonadism. Low libido with normal testosterone does not benefit from HCG. Comprehensive hormone workup including total testosterone, free testosterone, LH, FSH, prolactin, and SHBG is essential before testosterone-axis intervention.
“Testosterone replacement and HCG are interchangeable.”
HCG and exogenous testosterone have different mechanisms with different trade-offs. HCG stimulates endogenous testosterone production via LH-receptor activation, preserving testicular volume and fertility. Exogenous testosterone replaces testosterone directly but suppresses LH/FSH, reducing testicular volume and impairing fertility. Patient selection considers fertility plans and hypogonadism etiology.
“Kisspeptin is the new go-to for men with low desire.”
Kisspeptin Phase 2 evidence from the Dhillo group at Imperial College London is promising for next-generation low desire therapy. The compound is investigational with Phase 3 development ongoing. Not FDA-approved as of 2026. Validated FDA-approved options including testosterone replacement and HCG hold current evidence-graded positioning.
“I can self-treat low libido with peptides without seeing a doctor.”
Comprehensive evaluation by urology, endocrinology, men's health, or primary care identifies hormonal, medication, psychological, and metabolic contributors. Self-treatment bypasses essential workup. Validated FDA-approved options including testosterone replacement and HCG require prescriber evaluation per Endocrine Society guidelines.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Get comprehensive hormone workup.
Total testosterone, free testosterone, LH, FSH, prolactin, SHBG, TSH, and estradiol. Morning testing. Multiple tests for confirmation. Endocrine Society guidelines provide framework.
Establish urology, endocrinology, men's health, or primary care specialty.
Specialty evaluation determines appropriate therapy matching. Urology handles complex sexual health. Endocrinology handles complex hormonal evaluation. Men's health integrates disciplines.
Address contributing factors.
Medication review (SSRIs, opioids, finasteride), depression screening, sleep apnea evaluation, metabolic syndrome assessment, and weight management form comprehensive approach.
Match FDA-approved options to your etiology.
Hypogonadotropic hypogonadism: HCG or testosterone replacement. Primary hypogonadism: testosterone replacement. Specialty guidance ensures matching to fertility goals and individualized factors.
Optimize lifestyle foundations.
Weight management, regular exercise, adequate sleep, stress management, limited alcohol, smoking cessation, and treatment of comorbid sleep apnea form validated foundation.
Consider sex therapy through AASECT-certified therapists.
Psychological, relational, and behavioral factors contribute to low libido. Sex therapy addresses these factors alongside pharmacotherapy. AASECT certification identifies trained practitioners.
The regulatory landscape for low libido in men is dynamic. Testosterone replacement therapy formulations have evolved with multiple branded and generic options. HCG approval status remains established. Kisspeptin Phase 3 development at Imperial College London and partners is ongoing with potential FDA approval pending readout. Compounded peptides face regulatory scrutiny. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Is any peptide FDA-approved for low libido in men?
No peptide is FDA-approved for low libido in men specifically. HCG is FDA-approved for male hypogonadotropic hypogonadism with secondary libido relevance when low testosterone contributes. Exogenous testosterone replacement therapy is FDA-approved for hypogonadism with multiple formulations. Bremelanotide (Vyleesi) is FDA-approved for premenopausal female HSDD only with off-label male use lacking Phase 3 evidence. Kisspeptin is investigational. Tesamorelin is FDA-approved for HIV-lipodystrophy with absent low-libido-specific evidence.
Should I see a urologist or endocrinologist for low libido?
Yes. Low libido in men benefits from specialty evaluation. Urology handles complex sexual health concerns and hypogonadism workup. Endocrinology handles complex hormonal evaluation and pituitary disorders. Men's health specialty integrates multiple disciplines. Primary care can manage initial assessment and refer when indicated. Comprehensive evaluation includes hormone testing, mental health screening, medication review, and metabolic assessment per Endocrine Society guidelines.
What hormones should I test for low libido?
Comprehensive hormone testing typically includes total testosterone, free testosterone, and SHBG. Additional tests cover LH, FSH, prolactin, TSH, and estradiol. Testing should be done in the morning when testosterone levels are highest. Multiple tests may be needed for confirmation. Comprehensive interpretation by urology, endocrinology, or men's health considers patient-specific factors. Endocrine Society guidelines provide framework for diagnosis and treatment.
How does HCG compare to testosterone replacement therapy?
Both HCG and exogenous testosterone are FDA-approved for male hypogonadism with different mechanisms and trade-offs. HCG stimulates endogenous testosterone production via LH-receptor activation. The compound preserves testicular volume and supports fertility maintenance. Exogenous testosterone (gels, patches, injections, pellets) replaces testosterone directly but suppresses endogenous LH and FSH, reducing testicular volume and impairing fertility. HCG is appropriate for hypogonadotropic origin and fertility-preserving contexts. Exogenous TRT is appropriate for primary hypogonadism and patients without fertility concerns.
What about Bremelanotide (PT-141) for low libido in men?
Bremelanotide is FDA-approved as Vyleesi for premenopausal female HSDD only. Off-label male use for low libido or ED exists in some men's health clinic and integrative medicine contexts but is not FDA-approved and lacks Phase 3 outcome evidence. Mechanism is melanocortin-4 receptor agonism with central sexual desire pathway activation. Common side effects include nausea, flushing, and transient blood pressure elevation. Validated testosterone replacement therapy or HCG remain first-line for hypogonadism-related low libido in men.
Can medications cause low libido?
Yes. Multiple medications contribute to low libido in men. SSRIs and SNRIs (fluoxetine, sertraline, paroxetine, venlafaxine) commonly cause sexual side effects. Opioids reduce testosterone and libido. Finasteride (5-alpha-reductase inhibitor for BPH or hair loss) causes sexual side effects in some men. Beta-blockers can affect libido. Hormonal medications including some antiandrogens. Spironolactone has antiandrogenic effects. Medication review with prescriber identifies alternatives when sexual side effects contribute. Some side effects persist after discontinuation.
Does sleep apnea cause low libido?
Yes. Obstructive sleep apnea (OSA) is associated with reduced testosterone and low libido. Sleep fragmentation and intermittent hypoxia affect hypothalamic-pituitary-gonadal axis function. CPAP treatment for sleep apnea improves testosterone and libido in many patients. Sleep apnea workup with sleep study (polysomnography) is appropriate when risk factors are present. Risk factors include snoring, daytime sleepiness, obesity, and cardiovascular disease. Treatment of sleep apnea is foundational alongside any pharmacotherapy for low libido.
How does obesity affect low libido?
Obesity affects low libido through multiple pathways. Increased aromatase activity in adipose tissue converts testosterone to estradiol, reducing testosterone levels. Metabolic syndrome contributes to vascular dysfunction. Sleep apnea is more common in obesity. Inflammation affects hormonal balance. Weight management through dietary modification and exercise improves testosterone and libido in many patients. Treatment of comorbid metabolic syndrome including diabetes management is appropriate. Cardiometabolic optimization is foundational alongside testosterone-axis evaluation.
What is Kisspeptin and is it available for men with low libido?
Kisspeptin is an endogenous peptide that activates the kisspeptin receptor (KISS1R/GPR54) on hypothalamic GnRH neurons. Phase 2 trials from the Dhillo group at Imperial College London study intranasal kisspeptin in men with low sexual desire alongside women with HSDD. Trial results report increases in sexual desire and limbic activation. The compound is investigational and not FDA-approved. Phase 3 development is ongoing. Access in the United States is restricted to clinical trial enrollment. Validated FDA-approved options including testosterone replacement and HCG hold current evidence-graded positioning.
Should depression treatment come before peptides for low libido?
Yes when depression contributes. Depression is a major contributor to low libido in men. SSRIs and SNRIs commonly used for depression also cause sexual side effects, creating a complex picture. Comprehensive mental health assessment with PHQ-9 or other validated instruments identifies depression contribution. Treatment options balance antidepressant efficacy with sexual side effect profiles. Bupropion has fewer sexual side effects than SSRIs. Mirtazapine and vilazodone have lower rates of sexual side effects. Sex therapy addresses both depression and relationship contributors.
Are these peptides legal in the United States?
HCG is FDA-approved with multiple commercial products (Pregnyl, Novarel, Profasi, Ovidrel) by prescription for hypogonadism, fertility, and cryptorchidism. Bremelanotide is FDA-approved as Vyleesi for female HSDD only by prescription. Kisspeptin is investigational; access is through clinical trial enrollment. Tesamorelin is FDA-approved as Egrifta for HIV-lipodystrophy by prescription. Compounded peptides for off-label use are available through 503A pharmacies but represent non-validated practice for indications outside FDA-approved scope. Always work with a licensed prescriber within validated medical framework.
What are the side effects of testosterone replacement therapy?
Common testosterone replacement therapy side effects include polycythemia, worsening of sleep apnea, and acne. Additional effects include hair loss, gynecomastia, and testicular shrinkage. Cardiovascular safety has been studied with the TRAVERSE trial. Prostate considerations include monitoring PSA. Fertility effects are significant: exogenous TRT suppresses endogenous LH and FSH, reducing testicular volume and impairing fertility. HCG side effects are generally milder including injection site reactions, headache, mood changes, and gynecomastia at high doses. Monitoring under specialty guidance is appropriate.
What lifestyle factors improve low libido?
Multiple lifestyle factors have substantial validated evidence for low libido. Cardiovascular risk factor management protects sexual function. Weight management improves testosterone and libido. Regular aerobic exercise improves cardiovascular fitness and may improve testosterone. Resistance training supports testosterone and overall health. Adequate sleep optimizes testosterone production. Stress management addresses cortisol-related effects. Limited alcohol consumption preserves desire. Treatment of comorbid sleep apnea (CPAP) improves testosterone. Mediterranean dietary pattern supports overall health. Smoking cessation improves vascular function.
Should I consider sex therapy for low libido?
Yes when psychogenic or relational factors contribute. Psychogenic low libido includes depression, performance anxiety, relationship factors, body image, and trauma history. Sex therapy through AASECT-certified therapists addresses these factors alongside medical treatment. Couples therapy is appropriate when relationship factors contribute. Performance anxiety often responds to combination of pharmacotherapy and cognitive-behavioral approaches. The American Association of Sexuality Educators, Counselors and Therapists (AASECT) certifies sex therapists. Sex therapy is foundational alongside any pharmacotherapy.
How long does treatment for low libido take to work?
Treatment timelines vary by approach. HCG and testosterone replacement effects on testosterone develop over weeks to months. Subjective libido improvement often follows over 3 to 6 months of consistent treatment. Trough and peak testosterone levels guide dosing adjustments. Bremelanotide off-label male use targets pre-activity timing similar to female HSDD use. Kisspeptin is investigational. Comprehensive low libido treatment combines hormone therapy with lifestyle optimization, sex therapy, and treatment of comorbidities. Assessment of overall response typically requires 3 to 12 months.
What questions should I ask a doctor about low libido?
Ask: (1) What is my comprehensive hormone workup including total testosterone, free testosterone, LH, FSH, prolactin, SHBG, TSH, and estradiol? (2) Have I been screened for depression, sleep apnea, and metabolic syndrome contributors? (3) Are any of my medications contributing (SSRIs, opioids, finasteride, beta-blockers)? (4) For my specific etiology, what FDA-approved options apply (HCG, exogenous TRT, both)? (5) Have I optimized lifestyle foundations including weight, sleep, and exercise? (6) Should I consider sex therapy through an AASECT-certified therapist? (7) How do contraindications and monitoring requirements apply?
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.